West Pharmaceutical Services reported exceptional first-quarter results, driven by strong organic sales growth in base business and COVID-19-related products. High-value products continue to fuel increased gross and operating margins, leading to record earnings per share. Biologics and generics market units experienced strong double-digit growth, while pharma also saw notable expansion. Gross profit margin improved significantly to 40.5%, due to a favorable mix of products, production efficiencies, and sales price increases. The company's global manufacturing network has been instrumental in supporting demand, with ongoing expansion plans to meet anticipated core growth and COVID-19 vaccine requirements. West expects continued organic sales growth and margin expansion, leveraging their market-leading position in supporting patient health. Full-year sales are projected to reach $2.63-$2.655 billion, with adjusted diluted EPS in the range of $6.95-$7.10.